Last reviewed · How we verify
Cabotegravir LA + Rilpivirine LA
Cabotegravir and rilpivirine are long-acting antiretroviral agents that inhibit HIV integrase and reverse transcriptase, respectively, preventing viral replication.
Cabotegravir and rilpivirine are long-acting antiretroviral agents that inhibit HIV integrase and reverse transcriptase, respectively, preventing viral replication. Used for HIV-1 infection in treatment-experienced or treatment-naive adults as a long-acting injectable regimen.
At a glance
| Generic name | Cabotegravir LA + Rilpivirine LA |
|---|---|
| Sponsor | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia |
| Drug class | Antiretroviral combination (INSTI + NNRTI) |
| Target | HIV integrase and HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into host cell DNA. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks reverse transcriptase, preventing conversion of viral RNA to DNA. Together as long-acting formulations, they provide sustained HIV suppression with dosing every 4 weeks or every 2 months.
Approved indications
- HIV-1 infection in treatment-experienced or treatment-naive adults as a long-acting injectable regimen
Common side effects
- Injection site reactions
- Headache
- Fatigue
- Nausea
- Diarrhea
- Pyrexia
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
- A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 (PHASE3)
- Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of "HIV Units". (NA)
- Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs (PHASE2)
- More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (PHASE1, PHASE2)
- Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: